Crystagen

EDP tripeptide research reference · trade-name linkage and market sequences require verification

Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COACAS Confirm per batch COARUO

Research statusLimited patent and preclinical evidence; trade-name linkage is indirect; laboratory Research Use Only

Supplied formLinear tripeptide; H-Glu-Asp-Pro-OH (EDP)

Lead time14–21 days

Crystagen — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA

Crystagen — Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA · Representative packaging image · verify the ordered lot

Representative packaging image · verify the ordered lot

Decision summary

Key benefits

Research applications include EDP identity qualification, controlled lymphocyte or immune-cell models, senescence-related marker assays, replication of patent experiments and analytical comparison with heterogeneous Thymalin or other short peptides
Patent claims and observational extract programmes are hypotheses or context, not approved efficacy claims for isolated EDP.

Published research context is presented for literature orientation only. It is not a dosing, treatment or human-use instruction.

Qualification data

Specifications to confirm against the released lot

CAS: Confirm per batch COA
Formula: C₁₄H₂₁N₃O₈
Molecular weight: Approximately 359.33 Da
Appearance: Lot-specific lyophilized research peptide; confirm colour and cake condition on the released-lot COA
Purity: Lot-specific chromatographic purity and quantitative peptide content; confirm both on the released-lot COA · target, verify batch COA
Storage: Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, container, shipping range and any prepared-solution hold time require evidence for the exact EDP form, counterion, matrix and concentration; capsule or sublingual product labels do not apply.
MOQ: On request
Lead time: 14–21 days

PubChem CID 145455337

Qualification matrix

Identity, purity and content are separate release questions.

Identity

Confirm the stated molecule and supplied form. Start with the matching batch COA; request sequence-level evidence only when the buyer's written procedure requires it and availability or a separate scope has been agreed.

Purity

Review RP-HPLC method conditions, wavelength, integration and related-peak handling. A percentage without the method is not enough.

Content

Net peptide content is not the same as gross lyophilized powder weight. Ask which assay supports the stated amount and whether water/counter-ion is addressed.

Stability

Define long-term storage and transit exposure separately. Cold-chain can be quoted when the buyer’s risk assessment requires it and adds cost.

Research context

What researchers study about Crystagen

Crystagen is a trade name generally associated with synthetic H-Glu-Asp-Pro-OH, EDP. PubChem CID 145455337 and US Patent 8,057,810 B2 support the EDP tripeptide, formula C₁₄H₂₁N₃O₈ and molecular weight 359.33 Da, but the patent does not use the names Crystagen or AC-6. The trade-name linkage is indirect through a Khavinson patent-family listing. Later literature places EDP in the lineage of thymic-extract research, but does not prove it was naturally isolated as the active ingredient of Thymalin. Conflicting commercial sequences make exact sequence, termini, counterion and supplied form order-critical.

EDP identity and method development; controlled lymphocyte, immune-cell, senescence and gene-expression models; replication of patent experiments; and analytical comparison with Thymalin or related short peptides
These are laboratory applications, not clinical indications.

Mechanism context

The question the literature is testing

The patent reports lymphocyte proliferation/differentiation observations and proposes restoration of tissue-specific protein synthesis. Broader Khavinson literature proposes chromatin, DNA/histone and gene-expression effects for short peptides. No specific receptor or complete causal pathway has been independently validated for isolated EDP, and results from Thymalin cannot be transferred automatically.

Evidence map

Research routes and exposure context

Evidence tierMixed evidence context

Research areaKhavinson bioregulators

Routes reported in sources

OralSublingual

Dose / exposure contextProtocol-specific; verify the cited primary source

Routes and exposure contexts summarize cited studies or approved finished-product labels. They are not instructions for administering this RUO material; no customer dose is provided.

Evidence boundaries

Compatibility, limitations and decision context

Not for human or veterinary use and not a food or dietary supplement
Historical supplement labels and reports of tolerability do not establish safety, pregnancy guidance, interaction safety or administration suitability for this RUO lot
Follow the SDS, institutional controls and appropriate PPE.

Interactions reported in the literature

No controlled combination or drug-interaction evidence was identified
Pairings with Thymogen, Vilon, Thymosin Alpha-1, TB-500 or other bioregulators are commercial or research hypotheses, not validated synergy, compatibility or safety guidance.

Literature context is not a supplier release result or human-use instruction. Follow your institution's approved laboratory risk assessment.

Factory batch documentation

Crystagen factory batch COAs

Crystagen 20 mg Factory batch COA protected preview

Crystagen20 mg · WHJLP-CRY20-260420-C

Representative records, refreshed periodically

Published COAs show representative factory batches and may not be the latest available. For a current quote or shipment, our sales team can confirm the applicable lot and provide its COA.

Independent testing, arranged on request

Third-party reports are not routinely published. If independent verification is required, we can agree the laboratory, method, acceptance criteria and remedy before testing. If the agreed specification is not met, an appropriate resolution—including a refund where applicable—can be discussed under the agreed terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Help reviewing your COA

Need help reading a factory COA or third-party report? Our sales team can clarify test items, specifications and how the results relate to the lot under discussion.

Ask for the current packet, not a generic certificate

Require exact EDP sequence and termini, supplied form/counterion, theoretical and observed high-resolution intact mass, orthogonal sequence evidence, stability-indicating HPLC purity and impurity profile, quantitative peptide content, water/counterion/residuals and lot-specific stability
Sterility, bacterial endotoxin and bioburden are separate tests
EDP/TKD/KED/Pro-Gln-Asn or ingredient-list inconsistencies are identity failures; price, packaging or an uncited efficacy percentage is not quality evidence.

Released-batch COARP-HPLC result and method contextIdentity result appropriate to the moleculeWater / counter-ion context where relevantSDS and handling statementAdditional testing scoped on request

Available fills

Quote the fill and pack configuration you need

Reference SKUFillBase pack

CRYS-20MG20 mg10 vials

Handling

Storage in the lab and temperature during transit are different decisions

Follow the released-lot COA, SDS and formulation-specific stability statement. Temperature, light protection, container, shipping range and any prepared-solution hold time require evidence for the exact EDP form, counterion, matrix and concentration; capsule or sublingual product labels do not apply.

State destination, season, acceptable transit exposure and whether your protocol requires insulated or cold-chain service. Additional temperature-control cost is quoted explicitly.

Buyer FAQ

Terms to settle before the purchase order

Can a buyer arrange third-party testing?+

Yes. Testing must be performed by a mutually accepted, established specialist laboratory. Fee allocation, specification, sampling, method and acceptance rule must be agreed before testing; if an agreed independent result shows nonconformance, the remedy follows the signed order terms. Unless otherwise agreed in writing, the buyer pays the cost of this optional testing.

Does HPLC purity prove peptide content?+

No. Chromatographic purity describes the relative peak profile under a stated method. Identity, water, counter-ion, residual solvents and assay/content may require separate methods.

Is cold-chain shipping always required?+

Not always. Heat can accelerate degradation, especially during summer and long transit. Cold-chain reduces exposure but raises cost. State the destination and stability risk so the right service can be quoted.

How are payment terms handled?+

Available methods and milestones depend on order value, destination and project type. The pro forma invoice should state currency, bank details, fees, payment milestones and the release condition.

Why must the testing laboratory understand peptide chemistry?+

Free-base and salt forms, hydrophilic and hydrophobic sequences, aggregation and adsorption can change sample preparation and method suitability. Use a laboratory experienced with the molecule class.

External qualification references

WHO good storage and distribution practices IATA Temperature Control Regulations ISO/IEC 17025 laboratory competence 21 CFR 211.84 component testing and supplier COA controls

These are buyer-qualification references, not claims that this RUO material is regulated, certified or released under those frameworks. Applicability depends on the buyer's workflow and jurisdiction.

Selected sources

Literature behind the research context

Identity: PubChem CID 145455337 and US Patent 8,057,810 B2; patent experimental context: US Patent 8,057,810 B2; indirect trade-name linkage: Khavinson patent-family listing and IL 194499. Related but non-equivalent contexts: PMID 14523363 for Thymalin plus Epithalamin and PMC8654498 for Thymalin extract. These sources do not establish purified EDP clinical efficacy, human dose or pharmacokinetics.

01
Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application
United States Patent and Trademark Office (assignee: Peptidpro LLC) · 2011 · regulatory/IP document (issued US patent, not peer-reviewed journal article)
Open source
02
Кристаген (Kristagen) — БАД product monograph
RLSNET.ru commercial professional pharmaceutical reference directory · 2022 · commercial professional pharmaceutical reference-directory entry
Open source
03
Кристаген — пептиды тимуса, 20 капсул (product page)
peptid.ru (official Khavinson Peptides brand site) · 2024 · company/manufacturer product page
Open source

Product FAQ

Questions buyers ask about Crystagen

What identity is best supported for Crystagen?+

PubChem CID 145455337 and US Patent 8,057,810 B2 support synthetic H-Glu-Asp-Pro-OH, EDP, formula C₁₄H₂₁N₃O₈ and molecular weight 359.33 Da. The patent does not use the names Crystagen or AC-6; that linkage comes indirectly from a Khavinson patent-family listing. Market pages also publish conflicting sequences. The order and COA must therefore state exact N-to-C sequence, termini, form/counterion and orthogonal identity results.

Can evidence for Thymalin be assigned to purified EDP?+

No. Thymalin is a heterogeneous thymic extract, while EDP is one defined synthetic tripeptide. Observations for an extract, or for a Thymalin-plus-Epithalamin programme, cannot establish efficacy, safety or mechanism of isolated EDP. Such records provide lineage context only and must retain the exact tested material.

Which quality controls address market mislabelling?+

Require the full EDP sequence and termini, theoretical and observed high-resolution intact mass, orthogonal sequence evidence, chromatographic purity and impurity profile, quantitative peptide content, counterion, water and residual solvents, and lot-specific stability. Compare every label and COA field for internal consistency; an EDP, TKD, KED, Pro-Gln-Asn or ingredient-list mismatch is a critical identity failure.

Crystagen

Key benefits

Specifications to confirm against the released lot

Identity, purity and content are separate release questions.

What researchers study about Crystagen

The question the literature is testing

Research routes and exposure context

Compatibility, limitations and decision context

Interactions reported in the literature

Crystagen factory batch COAs

Ask for the current packet, not a generic certificate

Quote the fill and pack configuration you need

Storage in the lab and temperature during transit are different decisions

Terms to settle before the purchase order

Literature behind the research context

Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application

Кристаген (Kristagen) — БАД product monograph

Кристаген — пептиды тимуса, 20 капсул (product page)

Questions buyers ask about Crystagen

Compare adjacent molecules and documentation needs.

Thymalin

Cortagen

Vesugen

Cardiogen